Literature DB >> 25437196

Total lesion glycolysis as an IgG4-related disease activity marker.

Yoshinari Nakatsuka1, Tomohiro Handa, Yuji Nakamoto, Tomomi Nobashi, Hajime Yoshihuji, Kiminobu Tanizawa, Kohei Ikezoe, Akihiko Sokai, Takeshi Kubo, Toyohiro Hirai, Kazuo Chin, Kaori Togashi, Tsuneyo Mimori, Michiaki Mishima.   

Abstract

OBJECTIVES: 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) was reported to be useful for monitoring immunoglobulin G4-related disease (IgG4-RD); however, a quantitative FDG-PET/CT analysis such as total lesion glycolysis (TLG) has not yet been conducted. This study aimed to investigate whether TLG would correlate with serum markers in IgG4-RD, and the utility of TLG for disease monitoring.
METHODS: This retrospective study included 17 patients (12 men; median age, 62 years) who were followed up at Kyoto University Hospital and underwent FDG-PET/CT from April 2009 to November 2013. TLG was calculated for the involved lesions. Correlations between serum markers [IgG4, soluble IL-2 receptor (sIL-2R), lactate dehydrogenase (LDH), and C-reactive protein (CRP)] and TLG concomitant with FDG-PET/CT scans were investigated. Serial changes in TLG were assessed in patients who underwent follow-up FDG-PET/CT (n = 6).
RESULTS: The calculated median (IQL) TLG value was 154.8 (63.7-324.4). A significant correlation was found between the sIL-2R level and TLG (P = 0.001, rs = 0.763). In contrast, no correlations were found between the IgG4, LDH, or CRP levels and TLG. Increased or decreased TLG corresponded with clinical disease improvement or worsening.
CONCLUSIONS: TLG correlated significantly with the serum sIL-2R level and may be useful for disease monitoring in IgG4-RD.

Entities:  

Keywords:  FDG-PET; IgG4-related disease; Soluble IL-2 receptor; Total lesion glycolysis

Mesh:

Substances:

Year:  2014        PMID: 25437196     DOI: 10.3109/14397595.2014.990674

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  6 in total

Review 1.  IgG4-Related Disease: Beyond Glucocorticoids.

Authors:  Mitsuhiro Akiyama; Tsutomu Takeuchi
Journal:  Drugs Aging       Date:  2018-04       Impact factor: 3.923

2.  Enhanced IgG4 production by follicular helper 2 T cells and the involvement of follicular helper 1 T cells in the pathogenesis of IgG4-related disease.

Authors:  Mitsuhiro Akiyama; Hidekata Yasuoka; Kunihiro Yamaoka; Katsuya Suzuki; Yuko Kaneko; Harumi Kondo; Yoshiaki Kassai; Keiko Koga; Takahiro Miyazaki; Rimpei Morita; Akihiko Yoshimura; Tsutomu Takeuchi
Journal:  Arthritis Res Ther       Date:  2016-07-13       Impact factor: 5.156

3.  Soluble Interleukin-2 Receptor: A Potential Marker for Monitoring Disease Activity in IgG4-Related Disease.

Authors:  A F Karim; L E M Eurelings; R D Bansie; P M van Hagen; J A M van Laar; W A Dik
Journal:  Mediators Inflamm       Date:  2018-03-01       Impact factor: 4.711

4.  Disease activity and response to therapy monitored by [18F]FDG PET/CT using volume-based indices in IgG4-related disease.

Authors:  Katsuya Mitamura; Hanae Arai-Okuda; Yuka Yamamoto; Takashi Norikane; Yasukage Takami; Kengo Fujimoto; Risa Wakiya; Hiroki Ozaki; Hiroaki Dobashi; Yoshihiro Nishiyama
Journal:  EJNMMI Res       Date:  2020-12-09       Impact factor: 3.138

5.  FDG-PET/CT imaging parameters for predicting spontaneous regression of methotrexate-associated lymphoproliferative disorder in patients with rheumatoid arthritis.

Authors:  Tomohiro Kameda; Shusaku Nakashima; Katsuya Mitamura; Yuka Yamamoto; Takashi Norikane; Hiromi Shimada; Risa Wakiya; Mikiya Kato; Taichi Miyagi; Koichi Sugihara; Rina Mino; Mao Mizusaki; Norimitsu Kadowaki; Hiroaki Dobashi
Journal:  Sci Rep       Date:  2022-09-13       Impact factor: 4.996

6.  Role of FDG PET/CT in monitoring treatment response in patients with invasive fungal infections.

Authors:  Alfred O Ankrah; Lambert F R Span; Hans C Klein; Pim A de Jong; Rudi A J O Dierckx; Thomas C Kwee; Mike M Sathekge; Andor W J M Glaudemans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-21       Impact factor: 9.236

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.